Cargando…

Dupilumab-Induced Pancreatitis

Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring...

Descripción completa

Detalles Bibliográficos
Autores principales: Jasti, Vivek V., McCarthy, Sean T., Govani, Shail M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365188/
https://www.ncbi.nlm.nih.gov/pubmed/37492485
http://dx.doi.org/10.14309/crj.0000000000001106
_version_ 1785076993638793216
author Jasti, Vivek V.
McCarthy, Sean T.
Govani, Shail M.
author_facet Jasti, Vivek V.
McCarthy, Sean T.
Govani, Shail M.
author_sort Jasti, Vivek V.
collection PubMed
description Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring systems to identify DIP, we have identified another case of suspected DIP. In this study, we present a case of pancreatitis 10 days after initiation of dupilumab. An evaluation for other causes was unrevealing. As dupilumab use increases, providers should be aware of this possible adverse effect.
format Online
Article
Text
id pubmed-10365188
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-103651882023-07-25 Dupilumab-Induced Pancreatitis Jasti, Vivek V. McCarthy, Sean T. Govani, Shail M. ACG Case Rep J Case Report Drug-induced pancreatitis (DIP) is a rare cause of pancreatitis with an extensive and growing list of offending medications. Drawing a causative relationship between a medication and pancreatitis can be challenging, requiring a thorough workup to exclude other potential etiologies. By using scoring systems to identify DIP, we have identified another case of suspected DIP. In this study, we present a case of pancreatitis 10 days after initiation of dupilumab. An evaluation for other causes was unrevealing. As dupilumab use increases, providers should be aware of this possible adverse effect. Wolters Kluwer 2023-07-21 /pmc/articles/PMC10365188/ /pubmed/37492485 http://dx.doi.org/10.14309/crj.0000000000001106 Text en © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Jasti, Vivek V.
McCarthy, Sean T.
Govani, Shail M.
Dupilumab-Induced Pancreatitis
title Dupilumab-Induced Pancreatitis
title_full Dupilumab-Induced Pancreatitis
title_fullStr Dupilumab-Induced Pancreatitis
title_full_unstemmed Dupilumab-Induced Pancreatitis
title_short Dupilumab-Induced Pancreatitis
title_sort dupilumab-induced pancreatitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10365188/
https://www.ncbi.nlm.nih.gov/pubmed/37492485
http://dx.doi.org/10.14309/crj.0000000000001106
work_keys_str_mv AT jastivivekv dupilumabinducedpancreatitis
AT mccarthyseant dupilumabinducedpancreatitis
AT govanishailm dupilumabinducedpancreatitis